Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma
Journal of the National Comprehensive Cancer Network · 2026
DOI: 10.6004/jnccn.2026.7018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Bryant Morocho und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Surgical Oncology, Department of Surgery, Roger Williams Medical Center, Providence, RI. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
The role of adjuvant immunotherapy (IO) in the treatment of Merkel cell carcinoma (MCC) is currently being explored in clinical trials. Here we aim to evaluate the real-world impact of adjuvant IO on survival in patients with MCC.
Methods
A retrospective analysis of the National Cancer Database was performed to identify patients with stage I–III MCC. Our main predictor of interest was IO in an adjuvant setting, stratified by receipt of radiotherapy (RT). A multivariable Cox proportional hazards regression model with inverse probability treatment weighting was used to estimate overall survival.
Results
A total of 353 patients received adjuvant IO, while 5,340 underwent surgery without adjuvant therapy. Among patients who received adjuvant IO, 10.2% had stage I disease, 7.1% stage II, and 82.7% stage III. Overall, adjuvant IO was not associated with a difference in survival (hazard ratio [HR], 1.04; 95% CI, 0.86–1.26). Stratified analyses by stage demonstrated similar findings (stage I: HR, 1.4; 95% CI, 0.79–2.50; stage II: HR, 1.45; 95% CI, 0.67–3.13; stage III: HR, 0.98; 95% CI, 0.79–1.20). However, when an interaction term with RT was introduced with adjuvant IO, both treatments were associated with improved survival compared with surgery alone (HR, 0.53; 95% CI, 0.28–0.99), whereas adjuvant IO without RT was not associated with a significant survival difference (HR, 1.14; 95% CI, 0.83–1.60).
Conclusions
The association between adjuvant IO on survival may be modified by RT, which should be considered when interpreting current adjuvant IO trials in MCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- 1Division of Surgical Oncology, Department of Surgery, Roger Williams Medical Center, Providence, RI.
- 2Roger Williams Surgery and Cancer Outcomes Research and Equity (RWSCORE) Center, Roger Williams Medical Center, Providence, RI.
- 3Department of Surgery, Boston University School of Medicine, Boston, MA.
Zitieren
APA
Morocho, B., Lightfoot, S., Calvino, A. S., Somasundar, P., & Kwon, S. (2026). Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7018
Vancouver
Morocho B, Lightfoot S, Calvino AS, Somasundar P, Kwon S. Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7018
BibTeX
@article{Morocho2026,
author = {Morocho, Bryant and Lightfoot, Sasha and Calvino, Abdul Saied and Somasundar, Ponnandai and Kwon, Steve},
title = {Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
doi = {10.6004/jnccn.2026.7018}
}
EUVIMED